Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HPK enters the week with a sharp price rally colliding against a short book that has barely budged, creating one of the more interesting tensions in small-cap E&P right now.
The stock closed at $10.55 on Friday, up 10.5% on the week and 22% over the past month. That momentum is real. Peers moved too: APA gained 7.1% on the week and COP added 9.3%, so a rising oil-price tape is doing some of the work. But HPK's gain on Friday alone hit 6%, outpacing the sector. What makes the setup interesting is that this rally has arrived with a short book that has been quietly but steadily unwinding for six weeks, yet still accounts for a meaningful 6.4% of the free float.
Short interest is telling a story of slow but deliberate covering. The short position peaked near 9.6 million shares in early September and has since fallen to around 8 million, a decline of roughly 16% over the month. That is steady rather than panicked covering. Borrowing costs remain almost irrelevant at just over 1%, and borrow availability has actually loosened this week to 75.8%, up from around 47% to 48% a fortnight ago. The 52-week availability low was 0.05%, so the current level is far from any squeeze territory. There is no mechanical pressure forcing shorts to cover. Those who remain short are staying by choice. The ORTEX short score reinforces this: at 83 out of 100, it flags the stock as one where bearish positioning remains a meaningful part of the picture, even after the covering wave.
Options traders are marginally more cautious than usual, though not dramatically so. The put/call ratio has crept up to 0.18, about 1.5 standard deviations above its 20-day average of 0.16. That is a mild tilt toward protection rather than a pronounced defensive stance, and the ratio remains far below its 52-week high of 6.9. The options market is not flashing alarm.
The Street has been quiet on HPK and the most recent analyst data is stale. Roth Capital reinstated coverage with a Buy and a $12 target back in October 2025, and BofA initiated at Underperform with a $10 target in April 2025. With the stock now at $10.55, the BofA target is effectively at parity, while the Roth target implies modest upside. The EPS surprise factor score sits at the 99th percentile, meaning the company has consistently beaten estimates relative to the broader universe, a point bulls will lean on heading into the November 2 earnings date. The EV/EBITDA multiple has drifted up over the past 30 days, reflecting the price move rather than any fundamental revision.
Ownership here is heavily concentrated. The founding management entity, HighPeak Energy Management, LLC, holds 63% of shares. John DeJoria's family trust and Jack Hightower each filed Schedule 13D amendments in September 2025, collectively disclosing activist-level stakes. As of those filings, DeJoria held 12.25% and Hightower 9.8% through HighPeak Energy Partners. The disclosure caveat applies: these are event-driven filings around the 5% threshold and reflect positions as last reported, not necessarily today. Still, the picture that emerges is a company where insiders and founding entities own the overwhelming majority of the float, leaving a thin slice of freely traded shares. That concentration amplifies moves in both directions.
The earnings history offers a mixed picture. The August 2026 print saw the stock drop nearly 9% the following day before recovering most of that over five days. The prior event saw a 14.7% jump. With Q3 results due November 2, the next few weeks will determine whether the recent covering trend continues or stalls at current short levels.
See the live data behind this article on ORTEX.
Open HPK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
